Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

26.72
-0.3300-1.22%
Pre-market: 27.200.4767+1.78%04:04 EDT
Volume:1.49M
Turnover:40.18M
Market Cap:2.76B
PE:-7.84
High:27.50
Open:27.41
Low:26.70
Close:27.05
52wk High:28.23
52wk Low:8.20
Shares:103.41M
Float Shares:95.05M
Volume Ratio:1.26
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:6.86
PE(LYR):-8.76

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 06

Nurix Chief Legal Officer Christine Ring Disposes of USD 259,399.29 in Common Shares

Reuters
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

TIPRANKS
·
Jul 01

Nurix Therapeutics assumed with an Outperform at Oppenheimer

TIPRANKS
·
Jun 29

Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed

Simply Wall St.
·
Jun 29

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 28,935 Common Shares for $580,006

Reuters
·
Jun 26

Nurix Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Nurix Therapeutics Price Target Maintained With a $34.00/Share by Needham

Dow Jones
·
Jun 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 12

Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL

Reuters
·
Jun 11

Nurix Therapeutics - Reports 92.9% Objective Response Rate in Second Line Btki-Exposed, Bcl2i-NaÏVe Cll Patients

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Responses Observed in High-Risk, Btk Resistant, and CNS-Involved Cll Subgroups

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Phase 1a Data Shows 22.1 Month Median Pfs, 83% Orr in Heavily Pretreated Relapsed/Refractory Cll/Sll

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Bexobrutideg Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics to Report Updated Phase 1a/B Results for Btk Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory Cll/Sll and Promising Activity in Earlier Lines of Therapy

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)

TIPRANKS
·
Jun 09